Gilead wins OK for Sovaldi, but $1,000-a-day price criticized
This article was originally published in Scrip
Executive Summary
Right on schedule on 6 December, Gilead Sciences won the highly anticipated approval from the US FDA for Sovaldi (sofosbuvir), a once-daily oral nucleotide analog polymerase inhibitor, as part of a combination antiviral regimen to treat patients with chronic hepatitis C virus (HCV) genotypes 1, 2, 3 or 4 infection, including those with hepatocellular carcinoma awaiting liver transplantation and those with HCV/HIV-1 co-infection.